Laurus Labs shares tumble 4% despite 886% surge in Q2 PAT. Should you buy the dip?
Laurus Labs shares fell despite Q2FY26 PAT surging 886% to Rs 195 crore, revenue rising 35%, and EBITDA more than doubling, with margins expanding to 24.4%.
Laurus Labs shares fell despite Q2FY26 PAT surging 886% to Rs 195 crore, revenue rising 35%, and EBITDA more than doubling, with margins expanding to 24.4%.
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
